Azimilide for Atrial Fibrillation: Clinical Trial Results and Implications
- 1 September 2003
- journal article
- review article
- Published by Springer Nature in Cardiac Electrophysiology Review
- Vol. 7 (3) , 215-219
Abstract
Azimilide dihydrochloride (or azimilide) is a class III antiarrhythmic drug currently under investigation that has been tested in atrial fibrillation in four randomized, placebo-controlled clinical trials to assess efficacy and dose range. These investigational trials showed that doses of azimilide 100 and 125 mg once daily prolonged the time to symptomatic arrhythmia recurrence in patients with a history of symptomatic atrial fibrillation, atrial flutter or both. Doses of 75 mg or less were not useful in this indication. Safety of azimilide has been examined in several different types of studies. In a large randomized clinical trial of post-infarct patients, azimilide neither increased nor decreased mortality risk. In patients with supraventricular arrhythmias, the most common adverse effects reported by patients on azimilide were approximately equal in frequency with those on placebo: headache, asthenia, infection, diarrhea and dizziness. Infrequent cases of torsade de pointes and severe neutropenia were reported in patients taking azimilide. Azimilide is an investigational antiarrhythmic drug that has shown efficacy in patients with atrial fibrillation.Keywords
This publication has 7 references indexed in Scilit:
- Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-responseAmerican Heart Journal, 2002
- Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial FibrillationThe Journal of Clinical Pharmacology, 2002
- Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillationThe American Journal of Cardiology, 2001
- Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-responseJACC, 2000
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic AgentCardiovascular Drug Reviews, 1997
- Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.Circulation, 1989